A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Recruiting

Phase 2

AP01A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Sponsor:

Avalyn Pharma Inc.

Code:

NCT06329401

Conditions

Progressive Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AP01

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-03. This information was provided to ClinicalTrials.gov by Avalyn Pharma Inc. on 2025-04-25.